ERBB2 and ovarian carcinoma: Treatment of ovarian cancer cells with both Paclitaxel (which blocked the depolymerization of microtubule assembly in the mitotic spindle) and Carboplatin (a DNA alkylation chemical) decreased KDM6B content and was linked to an increase of the H3K27me3 mark on the HER2 promoter leading to its decreased expression and decreased invasive and migratory cell capacities [89].